Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Exome sequencing of patient-derived conditionally reprogrammed cells

PROVIDER: PRJEB23030 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR2173714_1.fastq.gz	Fastqsanger.gz
	ERR2173714_2.fastq.gz	Fastqsanger.gz
	ERR2249090_1.fastq.gz	Fastqsanger.gz
	ERR2249090_2.fastq.gz	Fastqsanger.gz
	ERR2249100_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 58

Similar Datasets

ena-DATASET-FIMM-19-02-2016-09:48:34:645-121 - samples

Project description:RNA sequence data for conditionally reprogrammed cells from patient HUB_5

| EGAD00001001923 | EGA

Conditionally reprogrammed cells from patient-derived xenograft to model neuroendocrine prostate cancer development

Project description:Conditionally reprogrammed cells from patient-derived xenograft to model neuroendocrine prostate cancer development

| PRJNA627360 | ENA

Conditionally reprogrammed (CRC) and feeder free SMAD inhibited (SMADi) expanded human nasal epithelial cells label-free LC-MS/MS

Project description:Discovery of therapies that are able to correct defective CFTR requires patient derived in vitro pre-clinical cell models to be developed. Two main approaches exist to expand bronchial and nasal cultures, such as conditionally reprogrammed cells (CRC) and feeder free dual SMAD inhibition (SMADi) to overcome senescence, low cell count, and increase passages. To mimic airway epithelium the expanded cells are differentiated at air liquid Interface (ALI). This project focused to compare the global proteome of ALI differentiated CRC and SMADi expanded HNECs both treated and untreated with CFTR corrector VX-809.

2021-12-05 | PXD018386 | Pride

Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer [WES]

Project description:Whole exome sequencing of matched patient-derived xenograft in vitro-in vivo models.

2018-01-31 | GSE109954 | GEO

Establishing 3D Organoid Models from Patient-Derived Conditionally Reprogrammed Cells to Bridge Preclinical and Clinical Insights in Pancreatic Cancer

Project description:Establishing 3D Organoid Models from Patient-Derived Conditionally Reprogrammed Cells to Bridge Preclinical and Clinical Insights in Pancreatic Cancer

| PRJNA1266152 | ENA

Heterogeneous immune and tumor clonal evolution patterns in liver cancer

Project description:Paired end whole exome sequencing for patient 10, matched normal and tumor

2020-02-01 | E-MTAB-8127 | biostudies-arrayexpress

Inherited BCL10 deficiency with impaired hematopoietic and non-hematopoietic immunity

Project description:Whole exome sequencing (WES) files of a patient suffering from a combined immunodeficiency, and his parents.

2014-10-31 | E-MTAB-2962 | biostudies-arrayexpress

Whole-exome sequencing of genomic DNA extracted from patient-derived melanoma cell lines grown in vitro.

Project description:Whole-exome sequencing was performed on DNA samples extracted from eight patient-derived melanoma cell lines grown in vitro in serum-free EGF/bFGF-containing medium. The aim of the experiment was to search for genetic alterations responsible for phenotypic diversity of melanoma cell lines reported at the level of cell morphology, activity of signaling pathways essential for melanoma development and progression, and response to drugs.

2018-07-12 | E-MTAB-6978 | biostudies-arrayexpress

Identification of ETO2 direct target genes through integration of transcriptomic (RNAseq) and chromatin binding location (ChIPseq)

Project description:Erythroid cell lines (HEL and K562) were conditionally invalidated for the ETO2 gene using the CRISPR/Cas9 system. Gene expression profiling (RNAseq) and chromatin immunoprecipitation followed by high-throughput sequencing (ChIPseq) to assess localization of ETO2, MYB, EP300, H3K27ac and H3K4me3 was performed in control and ETO2-deficient cells. ChIPseq analyses were also performed on cells from human AEL patient-derived xenograft models.

2023-07-02 | E-MTAB-10346 | biostudies-arrayexpress

Establishing 3D Organoid Models from Patient-Derived Conditionally Reprogrammed Cells to Bridge Preclinical and Clinical Insights in Pancreatic Cancer

Project description:Pancreatic cancer is a highly aggressive malignancy with limited therapeutic options. To address the limitations of traditional 2D cell culture models, we developed 3D organoid cultures from patient-derived conditionally reprogrammed cell (CRC) lines. These organoids retain the molecular and mutational profiles of the original tumor cells, providing a more accurate model for drug response prediction. Drug sensitivity assays using gemcitabine plus nab-paclitaxel (Abraxane) and FOLFIRINOX revealed that 3D organoids more closely reflect clinical outcomes than 2D cultures, with higher IC50 values consistent with in vivo drug resistance. This platform offers a promising approach for precision medicine in pancreatic cancer.

2025-06-16 | GSE297770 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data